30S Stock Overview A clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of treatments for rare disease patients in Sweden, Germany, Denmark, the United Kingdom, and Mexico. More details
Rewards Risk Analysis + 3 more risks
See All Risk Checks Capture your thoughts, links and company narrative
Saniona AB (publ) Competitors Price History & Performance
Summary of share price highs, lows and changes for Saniona Historical stock prices Current Share Price SEK 0.66 52 Week High SEK 0.71 52 Week Low SEK 0.12 Beta 0.91 1 Month Change 24.39% 3 Month Change 67.43% 1 Year Change 100.61% 3 Year Change -17.23% 5 Year Change -77.66% Change since IPO -77.48%
Recent News & Updates Saniona AB (publ) to Report Q2, 2025 Results on Aug 28, 2025
Saniona Initiates SAN711 Biomarker Study Oct 07
Saniona Receives Regulatory Approval for San711 Biomarker Study Sep 18
New major risk - Financial position Sep 02
Second quarter 2024 earnings released: kr0.18 loss per share (vs kr0.34 loss in 2Q 2023) Sep 01
New major risk - Share price stability Jun 07 See more updates Saniona AB (publ) to Report Q2, 2025 Results on Aug 28, 2025
Saniona Initiates SAN711 Biomarker Study Oct 07
Saniona Receives Regulatory Approval for San711 Biomarker Study Sep 18
New major risk - Financial position Sep 02
Second quarter 2024 earnings released: kr0.18 loss per share (vs kr0.34 loss in 2Q 2023) Sep 01
New major risk - Share price stability Jun 07
First quarter 2024 earnings released: kr0.08 loss per share (vs kr0.35 loss in 1Q 2023) May 30
Saniona AB (publ) to Report Fiscal Year 2023 Results on Apr 30, 2024 Mar 01
New major risk - Negative shareholders equity Mar 01
Full year 2023 earnings released: kr1.49 loss per share (vs kr3.93 loss in FY 2022) Mar 01
Saniona Announces the Selection of Its Proprietary GABAA A5 Negative Allosteric Modulator (NAM) Lead Compound, San2465 Jan 02
Saniona AB (publ) Strengthens Epilepsy Pipeline with Selection of SAN2355 as Clinical Candidate Dec 27
Third quarter 2023 earnings released: kr0.38 loss per share (vs kr0.28 profit in 3Q 2022) Dec 01 Saniona AB (publ) to Report Fiscal Year 2024 Results on Feb 27, 2025 Saniona AB (publ), Annual General Meeting, May 29, 2024
Saniona Promotes Kv7 Epilepsy Compound to Candidate Selection Phase Nov 22
New major risk - Revenue and earnings growth Sep 01
Second quarter 2023 earnings released: kr0.34 loss per share (vs kr1.42 loss in 2Q 2022) Sep 01
New minor risk - Shareholder dilution Aug 20
First quarter 2023 earnings released: kr0.35 loss per share (vs kr2.14 loss in 1Q 2022) May 26
Full year 2022 earnings released: kr3.93 loss per share (vs kr6.59 loss in FY 2021) Feb 24
Saniona AB Appoints Nomination Committee for the Annual General Meeting 2023 Nov 26
Third quarter 2022 earnings released: EPS: kr0.28 (vs kr1.50 loss in 3Q 2021) Nov 18 Saniona AB (publ) to Report Q1, 2023 Results on May 25, 2023
Insufficient new directors Nov 16
Saniona AB (publ) Announces Anti-Inflammatory and Anti-Fibrotic Candidate SAN903 Is Ready for Clinical Studies Nov 03
Second quarter 2022 earnings released: kr1.42 loss per share (vs kr1.67 loss in 2Q 2021) Aug 26
Saniona Progresses Its Kv7 Epilepsy Program into Lead Optimization Aug 17
Saniona Reports Positive Top Line Results from the SAN711 Phase 1 Clinical Trial Jul 01
Insufficient new directors Jun 29
Saniona’S Preclinical Candidate San903 Shows Robust Dampening of Fibrosis in Chronic Kidney Disease Model Jun 25
Saniona Provides Update on Ongoing Review of Tesofensine in Mexico May 21 Saniona Appoints Anita Milland as Chief Financial Officer, Effective April 30, 2022 Saniona Announces Voluntary Pause of Phase 2B Clinical Trials of Tesomet for Hypothalamic Obesity and Prader-Willi Syndrome
Full year 2021 earnings: EPS in line with expectations, revenues disappoint Feb 25
Saniona AB (publ) to Report Fiscal Year 2021 Final Results on Apr 29, 2022 Feb 25
Saniona Initiates Multiple Ascending Dose Stage of SAN711 Phase 1 Clinical Trial Feb 11
Saniona Initiates Phase 2b Clinical Trial of Tesomet for Prader-Willi Syndrome Dec 29
Third quarter 2021 earnings released: kr1.50 loss per share (vs kr1.24 loss in 3Q 2020) Nov 19
Second quarter 2021 earnings released: kr1.67 loss per share (vs kr1.24 loss in 2Q 2020) Aug 27
Saniona Initiates Phase 1 Clinical Trial of SAN711 Jul 01
Saniona to Present Preclinical Data on SAN711 at the 7th Congress of the European Academy of Neurology Jun 09
First quarter 2021 earnings released: kr1.34 loss per share (vs kr1.47 profit in 1Q 2020) May 28
Full year 2020 earnings released: kr1.79 loss per share (vs kr2.95 loss in FY 2019) Mar 18
Saniona Receives Feedback from U.S. FDA Providing a Regulatory Path Forward for Tesomet in Hypothalamic Obesity Mar 09
Saniona Receives U.S. FDA Orphan Drug Designation for Tesomet in Prader-Willi Syndrome Mar 04
New 90-day low: €1.81 Feb 11
Novartis AG (SWX:NOVN) completed the acquisition of Cadent Therapeutics, Inc. from a group of sellers. Jan 26
New 90-day low: €1.97 Jan 15 Saniona Announces Management Appointments
Co-Founder recently bought €11k worth of stock Dec 06
New 90-day low: €2.07 Dec 05
Third quarter 2020 earnings released: kr1.24 loss per share Dec 03
Third quarter 2020 earnings released: kr1.24 loss per share Dec 01 Saniona AB (publ) to Report Fiscal Year 2021 Results on Feb 24, 2022 Saniona AB (publ) Appoints Nomination Committee Members
Saniona Reports Positive Topline Results from Tesomet Phase 2 Open-Label Extension Study in Hypothalamic Obesity Nov 25
New 90-day low: €2.37 Oct 21
Saniona Receives Pre-IND Feedback from FDA on Regulatory Path for Tesomet in Prader-Willi Syndrome (PWS) and Hypothalamic Obesity (HO) Oct 10
Earnings released Aug 28
Saniona AB (publ) has completed a Follow-on Equity Offering in the amount of $64.999993 million. Aug 12
New 90-day high - €3.69 Aug 06
An unknown buyer acquired 3.96% stake in Scandion Oncology A/S (NGM:SCOL) from Saniona AB (publ) (OM:SANION) for for $2.3 million. Jul 30
New 90-day high - €2.83 Jul 20 Shareholder Returns 30S DE Biotechs DE Market 7D -4.5% 2.5% -0.4% 1Y 100.6% -10.2% 7.9%
See full shareholder returns
Return vs Market: 30S exceeded the German Market which returned 7.9% over the past year.
Price Volatility Is 30S's price volatile compared to industry and market? 30S volatility 30S Average Weekly Movement 38.0% Biotechs Industry Average Movement 7.4% Market Average Movement 4.9% 10% most volatile stocks in DE Market 11.8% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: 30S's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 30S's weekly volatility has increased from 23% to 38% over the past year.
About the Company Saniona AB (publ), a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of treatments for rare disease patients in Sweden, Germany, Denmark, the United Kingdom, and Mexico. It also develops medicines modulating ion channels. The company’s products include Tesofensine, a monoamine reuptake inhibitor that has completed Phase 3 clinical trial to treat people with obesity; and Tesomet, an oral investigational therapy, which is Phase 2b clinical trial for the treatment of hypothalamic obesity and Prader-Willi syndrome.
Show more Saniona AB (publ) Fundamentals Summary How do Saniona's earnings and revenue compare to its market cap? 30S fundamental statistics Market cap €69.03m Earnings (TTM ) -€7.62m Revenue (TTM ) €2.33m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 30S income statement (TTM ) Revenue SEK 26.66m Cost of Revenue SEK 5.29m Gross Profit SEK 21.38m Other Expenses SEK 108.55m Earnings -SEK 87.17m
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 27, 2025
Earnings per share (EPS) -0.78 Gross Margin 80.18% Net Profit Margin -326.94% Debt/Equity Ratio -192.3%
How did 30S perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/01/05 15:51 End of Day Share Price 2025/01/03 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Saniona AB (publ) is covered by 3 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Michael Novod Nordea Markets Jesper Ilsoe Nordea Markets Fredrik Thor Redeye
Show 0 more analysts 
